Palisade Bio (PALI) Current Assets (2010 - 2026)
Palisade Bio (PALI) posted quarterly Current Assets of $133.2 million for Q1 2026, up 1589.4% year-over-year from $7.9 million in Q1 2025, and down 0.73% quarter-over-quarter from $134.2 million in Q4 2025.
Palisade Bio (PALI) Current Assets (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Current Assets for 17 consecutive years, with $133.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 1589.4% year-over-year to $133.2 million; the TTM figure through Mar 2026 stood at $133.2 million (up 1589.4% YoY), while the FY2025 annual figure was $134.2 million, up 1179.03% from the prior year.
- Current Assets fell to $133.2 million in Q1 2026 per PALI's latest filing, from $134.2 million in the prior quarter.
- Across five years, Current Assets topped out at $134.2 million in Q4 2025 and bottomed at $6.4 million in Q2 2025.
- Historically, Current Assets has averaged $25.8 million across 5 years, with a median of $12.3 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets plunged 49.64% — and 2026, when it jumped 1589.4%.
- Palisade Bio's Current Assets stood at $14.7 million in 2022, then declined by 9.54% to $13.3 million in 2023, then retreated by 21.26% to $10.5 million in 2024, then jumped by 1179.03% to $134.2 million in 2025, then fell by 0.73% to $133.2 million in 2026.
- Business Quant data shows PALI's Current Assets at $133.2 million in Q1 2026, $134.2 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 127.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 127.26 Mn |
| Mar 31, 2026 | 133.24 Mn |
| Dec 31, 2025 | 134.22 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | 6.45 Mn |
| Mar 31, 2025 | 7.89 Mn |
| Dec 31, 2024 | 10.49 Mn |
| Sep 30, 2024 | 8.87 Mn |
| Jun 30, 2024 | 12.31 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | 13.33 Mn |
| Sep 30, 2023 | 16.27 Mn |
| Jun 30, 2023 | 17.41 Mn |
| Mar 31, 2023 | 14.31 Mn |
| Dec 31, 2022 | 14.73 Mn |
| Sep 30, 2022 | 15.16 Mn |
| Jun 30, 2022 | 7.42 Mn |
| Mar 31, 2022 | 8.26 Mn |
| Dec 31, 2021 | 11.51 Mn |
| Sep 30, 2021 | 16.09 Mn |